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Abstract  
Recent research suggests that the striatal specific protein Rhes may play a critical role in the 
behavioral and neurodegenerative process that occurs in Huntington’s Disease, but the exact role 
of Rhes is unclear. Farnesylation of Rhes is required for it to become biologically active. This 
study examines the influence of pharmacological inhibitors of farnsylation and geranyl-
geranylation on behavior in a 3NP model of Huntington’s. 
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1. Introduction 
1.1 Huntington’s Disease 
Huntington’s Disease (HD) is a neurodegenerative disorder that involves the unstable expansion 
of the trinucleotide repeat (CAG) coding for a poly-glutamine stretch on the Huntingtin gene on 
chromosome 4. This expansion results in a long tract of poly-glutamines in the N-terminus of the 
huntingtin (Htt) protein. Htt is normally expressed with as many as 34 CAG repeats. However, 
more than 37 repeats (Walker, 2007) results in the expression of a mutated huntingtin protein 
(mHtt). The expanded polyglutamine tract has been linked to incorrect protein folding (Fink, 
1999), and leads to the abnormal shape of the mHtt proteins. The mHtt protein forms aggregates 
in the striatum and cortex, consistent with HD pathology. Although aggregates are the primary 
pathological feature associated with HD, their contribution to toxicity and cell death is debatable.  
While HD pathology results in substantial damage to several areas of the brain, including the 
cortex, and in later stages of the disease the hippocampus and cerebellum (Vonsattal & Difiglia, 
1998), the majority of neurodegeneration is localized in the striatum. Although the Htt protein is 
expressed throughout the peripheral and central nervous system, the majority of damage from the 
disease occurs specifically in GABAergic medium spiny neurons (MSNs) which comprise 90-
95% of striatal neurons (Graveland, Williams, & DiFiglia 1985; Albin, Reiner, Anderson, Dure, 
Handelin, Balfour et al., 1992). Additionally, post mortem findings indicate a greater number of 
aggregates in the lesser damaged cortex than in the degenerated striatum (Gutekunst, Li, Yi, 
Mulroy, Kuemmerle, Jones, et al., 1999), suggesting the aggregates are not directly associated 
with cell death.  
2 
 
A member of the Ras protein signaling family, Rhes, is expressed abundantly and selectively in 
striatal neurons (Falk et al., 1999). Due to its restricted expression, the Rhes protein has become 
a promising target for understanding the neurodegenerative process in HD. Overexpression of 
Rhes in cultured cells that also over-express mHtt has been shown to reduce cell survival by 
50%, whereas overexpression of either mHtt or Rhes alone did not result in a decrease in cell 
survival (Subramaniam, Sixt, Barrow & Snyder, 2009). However, when Rhes expression was 
diminished, the reduction in cell loss was reversed so that cell survival increased. Attenuation of 
Rhes has also shown promise in animal models of HD.  HD mice bred with Rhes knockout (KO) 
mice show significant delay in the onset of HD symptoms (Baiamonte, Lee, Brewer, Spano & 
LaHoste, 2013). Recently, Rhes KO mice were shown to be protected from striatal damage 
(Mealer, Subramaniam & Snyder, 2013) following 3-nitropropionic acid (3NP) treatment, a 
striatal lesion model of HD. The 3NP model is a mitochondrial complex II inhibitor, which 
creates a striatal specific lesion, as well as motor and behavioral symptoms similar to HD while 
sparing neurons outside of the striatum.  
1.2 Huntington’s Disease and Behavior 
Early indications of HD motor disturbances are found in the fingers, toes and small facial 
muscles. The muscle twitches may not be visible or may even be mistaken as signs of 
nervousness. The disturbances eventually move from distal to more proximal and axial areas. 
Hyperkinesia and hypokinesia cause difficulties in walking and standing. Saccadic eye 
movements are another early abnormality associated with HD as well as chorea, with akinesia 
and dystonia occuring in later stages of the disease. (Penney et al.,1990).  
Psychiatric symptoms of HD usually emerge before motor symptoms, but are often difficult to 
diagnosis in comparison with outward motor disturbances. However, anxiety and depression are 
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frequently observed in HD patients (Walker 2007). A recent study matching depressed HD 
patients with depressed patients from the general population found no significant difference in 
clinical features of depression based on the Hospital Anxiety and Depression Scale, Beck 
Depression Inventory, Test for Anhedonia questionnaire and a slightly modified Montgomery 
Asberg Depression Rating Scale (Scaria & Craufurd, 2014).  In addition to depressive symptoms, 
feelings of guilt, anxiety and low self-esteem are also frequently reported. Ninety-eight percent 
of HD patients in one study exhibited neuropsychiatric symptoms (Paulsen, Ready, Hamilton, 
Mega & Cummings, 2014). The most common symptoms were dysphoria, agitation, irritability, 
apathy and anxiety ranging from mild to severe and independent of cognitive or motor aspects of 
the disease.  
Currently, a diagnostic tool, the HD Behavioral Questionnaire (HDBQ), is being developed in 
order to capture psychiatric symptoms of HD while taking into consideration motor and 
cognitive disturbances associated with the disease. The HDBQ is a reliable instrument for 
screening behavioral changes in individuals with or at risk for HD, and is particularly important 
as these behavioral changes can affect quality of life for both the patient and caregiver (Corey-
Bloom, Herndon, Breen, Huynh & Gilbert, 2014).  
Consistent with the striatal neurodegenerative features of HD, presentation of both motor and 
psychiatric disorders likely involve striatal abnormalities (Crittenden & Graybiel 2011). The 
cortico-striatal pathway, along with dopaminergic innervations, is the major input to the striatum. 
HD has been associated with changes to the frontostriatal loop, which may account for a loss of 
cognitive flexibility (Kirch et al. 2013). Additional changes in synaptic plasticity in the 
corticostriatal pathway (Cummings, et al. 2007) may underlie early cognitive behavioral deficits 
by altering striatal information processing and transfer within basal ganglia-thalamo-cortical 
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loops. Striatal astrocytes and neurons have an increased vulnerability to calcium load, and striatal 
astrocytes have a lower mitochondrial buffering compared to cortical astrocytes (Oliveira and 
Goncalves 2009). Striatal GABAergic medium-sized spiny neurons (MSNs), in particular seem 
to be selectively vulnerable to metabolic stress, which may contribute to the selective loss of 
these neurons in HD. 
 The striatum is a part of the larger basal ganglia which includes two circuits, dorsal and ventral, 
comprised of several smaller areas of the brain.  The ventral tegmental area (VTA) and nucleus 
accumbens (NAc) together form the ventral pathway (Groenewegen, Wright, Beijer, & Voorn, 
2006). This circuit of the striatum is associated with the recognition of salient elements in the 
environment, and may be involved in symptoms such as anhedonia, loss of interest or passive 
behavior.  A second circuit, the dorsal pathway, is associated with downstream regulation of the 
motor cortex and motor learning, and is formed by the pallidum, substantia nigra pars compacta 
(SNpc), and subthalamic nucleus (STN).  
The MSNs that make up the majority of striatal neurons project to other areas of the brain 
through two pathways: direct and indirect. MSNs in the direct pathway project to the internal 
division of the globus pallidus (GPi) and the substantia nigra pars reticulata (SNpr), which in 
turn project to the ventroanterior and ventrolateral thalamus (VTh). The VTh projects to upper 
motor neurons in the primary motor cortex (Gerfen & Surmeier, 2011). In addition, the SNpr 
projects to the deep layer of the superior colliculus, and controls rapid eye movements 
(saccades), which is often one of the earliest reported motor symptoms of HD (Penney et al., 
1990). MSNs in the indirect pathway project to the external segment of the globus pallidus (GPe) 
which then project to the STN prior to innervating the SNpr.  
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MSNs receive input from three different sources: dopamine (DA) from the SNpc; glutamate 
from the cortex and thalamus; and GABA from striatal interneurons and other MSNs (Cha et al., 
1999; Luthi-Carter, et al., 2000). Additionally, the direct and indirect pathways express different 
proteins (Andre, Cepeda & Levine, 2010). The direct pathway primarily expresses DA D1-like 
receptors (D1 & D5). The indirect pathway highly expresses DA D2-like receptors (D2, D3, D4), 
which are among the first neurons to die during the early stages of the disease. 
NMDA receptors on MSNs are associated with altered calcium homeostasis, mitochondrial 
membrane depolarization, oxidative stress and caspase activation (Andre, Cepeda & Levine, 
2010). NMDA and AMPA receptor function increase with D1-like receptor activity due to 
several signaling pathways including cAMP and voltage-gated Ca2+ channels, and decrease with 
D2-like receptor activity. Normally DA modulates glutamate-induced excitation in the basal 
ganglia and cortex, but the balance between these systems is disturbed in HD. Overactivity of 
glutamatergic neurons is believed to lead to excitotoxicity and striatal changes, while altered 
dopaminergic neurotransmission has also been implicated in HD pathology including evidence 
of early stage increases in dopamine and later stage decreases (Cyr, Sotnikova, Gainetdinov, 
Caron 2006; Stack, et al., 2007; Crook and Houseman, 2012).  
1.3 Rhes  
Interestingly, Rhes has been implicated in dopaminergic and striatal function through regulation 
of dopamine supersensitivity (Harrison and LaHoste, 2006). Removal of dopaminergic input to 
the striatum leads to a reduction of Rhes mRNA, possibly contributing to the supersensitive 
response to DA observed in the striatal tissue following removal. Rhes related signal 
transduction applies also to neurons of the indirect striatopallidal pathway, implicating Rhes as a 
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partner in dopamine transmission, mediated through cAMP/PKA signaling (Errico, et al., 2008). 
Rhes inhibits behaviors stimulated by D2 receptor stimulation or D1/D2 receptor synergism, and 
facilitates the D1-specific behavior of grooming. Behaviors including locomotor activity and 
anxiety are also influenced by Rhes expression (Quintero, Spano, LaHoste, and Harrison, 2008). 
1.3.1 Rhes and AKT  
Striatal D2 receptors signal through G proteins, and also by promoting the formation of a striatal 
multi-protein complex which includes β-arrestin2, AKT and Protein Phosphatase 2A (PP2A). 
Upon formation of this complex, PP2a dephosphorylates and deactivates AKT.  AKT, also 
known as Protein Kinase B (PKB), is a serine/theorine-specific protein kinase that plays a key 
role in apoptosis, cell proliferation, transcription and cell migration as well as the development of 
diabetes and  cancer (Cantley, 2002; Sarbassov, Guertin., Ali & Sabatini, 2005). AKT activation 
levels are inversely related to activation of the dopamine receptor pathway (Souza, Romano-
Silva, Tropepe, 2011), and AKT has recently been recognized as an important factor in 
neurotransmission and mental illness (Kitagishi, Kobayahi, Kikuta & Matsuda, 2012). Recent 
evidence suggests that Rhes interacts with β-arrestin 2 to form the protein complex, and this 
interaction is necessary for PP2A to dephosphorylate and deactivate AKT (Harrison, Muller, 
Spano, 2014).  
Lithium treatment disrupts the formation of this striatal complex and increases levels of AKT 
phopsphorylation and activation. Rhes KO mice develop a lithium-treated phenotype (Harrison, 
Muller, Spano, 2014), as they express increased basal AKT phosphorylation following treatment 
with a D1/D2 agonist that is not further altered by lithium. Although, lithium is primarily 
recognized as treatment for mood disorders, its attenuating effect on mood requires AKT 
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phosphorylation (Pan et al., 2011), and it has been successfully used to treat motor symptoms of 
HD (Sarkar, Krishna, Imarisio, Saiki, O’Kane & Rubinsztein, 2008).  
Rhes also influences AKT signaling via another pathway in a seemingly contradictory manner. 
Growth factors, such as Insulin-like Growth Factor-1 (IGF-1), activate Phosphoinositide 3-
Kinase (PI3K), which primarily targets AKT for phosphorylation (Cantley, 2002). Insulin 
signaling is initiated when IGF-1 binds to its receptor, and activates the tyrosine kinase domain 
of the receptor. Insulin receptor substrate-1 (IRS-1) then binds to the activated receptor, and 
functions as the binding and activation site for PI3K, beginning the cell survival cascade. 
Although Rhes is necessary for dephosphorylation and deactivation of AKT, Rhes also enhances 
growth factor-mediated AKT phosphorylation and activation by binding with p85, the regulatory 
subunit of PI3K and by directly interacting with AKT and facilitating its movement to the 
membrane to initiate signaling (Bang, Steenstra & Kim, 2013), suggesting that Rhes may 
function as a critical bridge between PI3K and AKT. The authors further speculate that given the 
inverse relationship between DA activation, as well as the relationship between DA 
supersensitivity and Rhes expression, DA supersensitivity may lead to a decrease in Rhes 
expression and reduced AKT activity.     
Insulin signaling promotes cell growth and proliferation via AKT, and involves both Insulin and 
IGF-1. The Insulin receptor substrates (IRS1/2) intermediate receptor signaling inside of the cell 
for activated cell surface receptors. Like IGF-1 bound to its receptor, Insulin bound to the Insulin 
receptor (IR) also activates the tyrosine kinase domain and binding of IRS-1/2. Bound IRS1/2 
then activates several downstream pathways including PI3K/AKT (Nemoto et al., 2010; 
Ramalingam & Kim, 2014). Activation of the insulin receptor has a direct effect on 
neurotransmission and primes synapses for the induction of LTP following the binding of IRS-1 
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and IRS-2 to PI3K. IRS-1/2 bound with PI3K can then phosphorylate NMDA receptors to 
increase the opening associated with the Ca2+ channel (Hilscher, 2011) to induce LTP.  
1.3.2 Rhes and Thyroid Hormone 
Rhes is primarily expressed in the striatum, but has also been found in select peripheral tissues, 
and is dependent on thyroid hormone (TH) for expression (Verma, Kumar & Thapliyal, 2014). 
Notably, Rhes is also expressed in thyroid tissue and additionally has been shown to inhibit the 
functional activity of the thyroid stimulating hormone receptor (Agretti et al., 2007), possibly 
suggesting a role for Rhes in regulation of its own expression. TH is deregulated in HD, and the 
striatal protein protein µ-crystallin (Crym), a key regulator of TH may link TH deregulation and 
striatal vulnerability to mHtt, as overexpression of Cyrm in striatal MSNs is neuroprotective 
against N-terminal fragment mHtt toxicity in vivo (Francelle et al., 2014). Cyrm expression is 
reduced in HD, which may in turn either influence or be influenced by Rhes expression 
depending on interactions with TH. 
TH has also been shown to regulate IGF-1 expression (Harakawa et al., 1990), and inhibit IGF-1 
stimulated glucose uptake and cell proliferation (Incerpi et al., 2013), suggesting an additional 
link to Rhes expression and AKT phosphorylation mediated by insulin signaling. While the 
majority of HD symptoms result from damage to the central nervous system, the conflicting 
influence of Rhes on Insulin signaling and subsequent AKT activation and deactivation, may 
also clarify HD related changes in the peripheral nervous system. 
1.3.3 Rhes and Insulin Signaling 
Rhes is also expressed in pancreatic β-cells, where it may regulate the secretion of insulin (Chan 
et al., 2002; Verma, Kumar & Thapliyal, 2014). Pancreatic β-cells release insulin in response to 
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high levels of glucose. The insulin then circulates through the bloodstream until it binds to an 
insulin receptor in either the peripheral nervous system or central nervous system. Insulin 
resistance is a normal occurrence; however, when it co-occurs with impaired insulin secretion it 
contributes to type 2 diabetes (Withers & White, 1999). Pancreatic β-cells initially increase 
insulin secretion to compensate for hyperglycemia induced by insulin resistance (Rui et al., 
2001). If the hyperinsulinemia and hyperglycemia persist, insulin action may become impaired 
and diabetes may develop. 
In addition to neurological defects, HD is also associated with an increased incidence of diabetes 
(Podolsky, Leopold & Sax, 1972; Hu, Liang & Yu, 2014). Recently, a case study was published 
describing a 40 year old type 1 diabetic presenting symptoms of hyperglycemic induced chorea-
ballism, or extreme choreatic movement. Although the patient recovered from the chorea-ballism 
after being treated with fluids and insulin, mild choreatic movement persisted (Hashimoto et al., 
2012). Magnetic resonance imaging and DNA analysis revealed HD, suggesting a possible role 
for the acute influence of insulin on HD motor behavior. 
Transgenic mouse models of HD show progressive alterations in glucose levels that eventually 
result in the development of insulin deficiency and diabetes; altered pancreatic islets; and an age 
dependent reduction in insulin mRNA expression (Andreassen et al., 2002). The polyglutamine 
expansion tract in the Htt protein is thought to disrupt expression of transcription factors in 
pancreatic β-cells and result in insulin deficiency and diabetes (Björkqvist et al., 2005).  
Preferential Rhes expression in β-cells further supports a role for the involvement of Rhes in the 
selective toxicity of the ubiquitously expressed Htt protein.  Binding partners of Htt may also 
interact with Rhes to increase toxic effects. For example, Huntingtin-Associated Protein 1 
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(HAP1) is also expressed in pancreatic β-cells, and, was the first binding partner identified with 
Htt. Hap1 aids in intracellular processes which are disrupted by the presence of mHtt.  Hap1 KO 
mice show decreased amounts of insulin-containing vesicles at docking sites in β-cell 
membranes (Cape, 2010), suggesting HAP1 may be an important target for further understanding 
HD related impairment of β-cell insulin release and mHtt toxicity.  
AKT is also implicated in diabetes, and likely involves the multi protein complex required for 
AKT dephosphorylation. Loss of β-arrestin 2 results in defective AKT activation. AKT in an 
inactive dephosphorylated state inhibits insulin signaling, and contributes to insulin resistance 
(Teruel, Hernandez & Lorenzo, 2001). Peripheral administration of IGF-1 activates AKT, 
enhances insulin levels and protects against diabetic features in an animal model of Huntington's 
disease (Duarte et al., 2011).  
Insulin and IGF-1 decrease mitochondrial reactive oxygen species (ROS) induced by mHtt, and 
normalize mitochondrial activity of the antioxidant defense Superoxide Dismutases (SOD). 
Insulin signaling also increases AKT phosphorylayion and mitochondrial-encoded cytochrome c 
oxidase II, in mitochondria of insulin- and IGF-1 treated striatal cells (Ribeiro, Rosenstock, 
Oliveira, Oliveira & Rego, 2014). Insulin/IGF-1-treated mHtt striatal cells also showed reduced 
apoptotic features. 
Insulin signaled AKT activation inactivates proapoptotic proteins such as glycogen synthase 
kinase-3 (GSK-3b), Bad, and the forkhead transcription factors (FOX) (Fort et al. 2010) which 
are activated upon decreased survival signals, increased cellular stress, or both. AKT 
phosphorylates FOXO so that it becomes a substrate of ubiquitin ligase. Once a protein is 
ubiquitinated, it is tagged for degradation and broken down by the proteaosome. 
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 Ubiquitin ligase deficiency accelerates disease phenotype and increases global aggregate load in 
an animal model of HD (Maheshwari,et al., 2014). SUMOylation (Small Ubiquitin-like 
MOdifier), another post-translational modification, may serve as a necessary primer for 
ubiquitination, and stimulate protein ubiquitination and degradation (Wei & Lin, 2012).  
SUMOylation cell culture studies show that mHtt is sumoylated by Rhes. Rhes expression 
decreases mHtt aggregation and elicits neurotoxicity by increasing soluble levels of fragmented 
mHTT in addition to significantly reducing mHtt ubiquitination(Subramaniam, Sixt, Barrow & 
Snyder, 2009). Rhes also binds with much stronger affinity to mHtt compared to wild type Htt 
(Subramaniam, Sixt, Barrow & Snyder, 2009). SUMO was recently shown to be a key regulator 
of AKT phosphorylation while down-modulation of SUMO diminishes AKT and cell 
proliferation. Additionally, an AKT SUMOylation mutant displayed reduced activation, and 
decreased anti-apoptotic and pro-tumoral activities (de la Cruz-Herrera et al., 2014), possibly 
indicating a normally protective function of Rhes in protein degradation which becomes toxic in 
the presence of fragmented mHtt.  
1.3.4 Rhes and mHtt: Autophagy and Apoptosis  
In addition to the ubiquitin-proteasome system, proteins may also be depredated via autophagy, a 
lysosomal degradation pathway. The mammalian Target of Rapamycin (mTOR) is typically 
associated with the promotion of cell survival via phosphorylation of AKT, and is an important 
regulator of autophagy. However, many researchers intensely debate whether autophagy is 
involved in maintenance and cell survival, or is a necessary component of apoptosis (Levine  & 
Yuan, 2005; Nixon, 2006; Denton et al., 2009). Autophagy and apoptosis may be activated by 
common upstream signals that sometimes results in combined autophagy and apoptosis, or the 
cell switching between the two responses in a mutually exclusive manner. Specifically, the 
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shared apoptotic and autophagic pathways can either link or polarize these processes (Maiuri, 
Zalckvar, Kimchi & Kroemer, 2007). 
mTOR was discovered in mammals after the discovery of yeast Target of Rapamycin (TOR). 
Like TOR, mTOR consists of two distinct complexes: mTOR Complex1 (mTORC1) and 
Complex 2 (mTORC2). Rapamycin, an inhibitor of mTOR and TOR activates autophagy, but 
TORC2 and mTORC2 are insensitive to acute Rapamycin administration (Jacinto et al., 2004). 
mTORC1 activates the translational regulator S6K (S6 kinase), leading to increased protein 
synthesis in the presence of nutrients while mTORC2 responds to the presence of growth factors 
such as insulin by phosphorylating AKT. Moreover, chronic Rapamycin administration impairs 
glucose tolerance and insulin action, and is mediated by increased mTORC2 signaling and its 
negative feedback regulation of IRS-1. mTORC1 promotes phosphorylation and down-regulation 
of IGF-1 while mTORC2 mediates IRS-1 degredation (Sarbassov, et al., 2006; DeStefano & 
Jacinto, 2013).  
 Rhes was recently shown to bind to and activate mTORC1, but also appeared to influence 
mTORC2 in a study of Rhes KO mice (Subramaniam et al., 2013). Rhes KO mice display 
reduced mTOR, were predicted to inhibit autophagy secondary to mTOR activation. However, a 
follow up study showed that Rhes behaves in the opposite manner (Mealer, Murray, Shahani, 
Subramaniam & Snyder, 2014), and actually activates autophagy independent of mTOR by 
competitively binding to autophagy regulator Beclin-1 (Bcl-1) and decreasing its inhibitory 
interaction with Beclin-2 (Bcl-2). 
The mitochondrial pathway to cell death is regulated by Bcl-2 family proteins which include Bcl-
2, BH3 (the BCL-2 homology 3), Bax (BCL-2-associated X protein) and Bak (BCL-2 
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antagonist/killer). BH3 signals the start of apoptosis while Bcl-2 gaurds survival and Bax and 
Bak  promote apoptosis (Czabotar, Lessene, Strasser & Adams, 2014). These proteins interact on 
the mitochondrial membrane to determine apoptosis based on combined signaling. While it is 
widely believed that Bcl-2 inhibits autophagy by binding to Bcl-1 and blocking its function, 
recent evidence suggests that Bcl-2 is only indirectly involved in autophagy by inhibiting Bax 
and Bak, and that in the absence of Bax and Bak, autophagy cannot be stimulated (Lindqvist, 
Heinlein, Huangn & Vaux, 2014).  Inhibiting Bcl-2 in the absence of Bax and Bak stimulated 
autophagy, but also correlated with increased cell death. Additionally, increasing Bcl-2 should 
sequester Bcl-1 and inhibit autophagy, but no differences in autophagy were found following 
upregulation of Bcl-2. The authors propose a model where apoptosis induces autophagy, and 
suggest that autophagy does not significantly induce cell death in the absence of Bax and Bak.  
Once the apoptotic threshold is met via signaling of the Bcl-2 family, apoptogenic products are 
released into the cytosol, such as cytochrome c (COX). Interestingly, COX was increased 
following AKT phosphorylation by insulin treatment of striatal cells which reduced apoptosis 
(Ribeiro, Rosenstock, Oliveira, Oliveira & Rego, 2014) suggesting a role for insulin signaling in 
both  proliferation and apoptosis. 
Insulin also diminished oxidative damage due to lactate dehydrogenase (LDH), nitric oxide 
(NO), reactive oxygen species (ROS) and calcium ion (Ca2+) in neuronal cells (Gurzov & 
Eizirik, 2011). A follow up study in glia cells revealed that Insulin is protective due to activation 
of AKT, and upregulation of Bcl-2 by preventing Bax and Bax/Bcl-2 ratio, which is associated 
with apoptosis when the ratio increases. The Bcl-2 family is crucial to pancreatic β-cell 
mitochondrial apoptosis, and members regulate glucose metabolism and β-cell function (Gurzov 
& Eizirik, 2011). The combined role of Bcl-2 and Bcl-x is crucial for mitochondrial integrity and 
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β-cell survival, and involves metabolic signaling, Ca2+ homeostasis, and insulin secretion. 
Further, Bcl-2 and Bcl-x suppress the β-cell response to glucose, suggesting the Bcl-2 family is 
involved in normal cell function in addition to survival (Luciani et al., 2013). Lithium treatment 
prevented the decrease of striatal Bcl-2, and attenuated the increase of striatal Bax in a 
dopaminergic lesion model. Additionally, lithium increased striatal Bcl-2 in both lesioned and 
control mice (Youdim & Arraf, 2004); further indicating a role for Insulin signaling, AKT 
phosphorylation, and ultimately Rhes in both normal cell function and pathology.  
Given the complex and often conflicting roles of Rhes in cell signaling, it is difficult to 
determine how decreased Rhes expression is protective in HD. Because Rhes appears to be 
involved in multiple processes that regulate normal cell function, cell survival and cell death, 
manipulation of Rhes expression would seem to interfere with these processes in unpredictable 
ways. Although, mHtt is ubiquitously expressed throughout the body in HD, the majority of 
damage occurs in the select organs that express Rhes (e.g. striatum, pancreas). Despite 
localization in the CNS versus the PNS, damage occurring in these organs seems to involve the 
same cellular processes (e.g. AKT/mTOR), and Rhes is directly involved in both the activation 
and deactivation of these signals which promote survival and apoptosis.   
Many theories link neuronal death in HD to an increase in apoptotic signaling. One theory even 
suggests that midlife onset of HD may be an evolutionary tradeoff of reduced cancer risk during 
fertile years as a result of increased apoptotic activity (Turner, Goldacre & Goldacre, 2013). 
Interestingly, this theory is supported by studies showing reduced risk of cancer in HD (Sørensen 
& Fenger, 1992; Turner, Goldacre & Goldacre, 2013). Huntingtin is a substrate for the protease 
apopain8 which belong to a family of cysteine proteases that play a crucial role in the apoptotic 
pathway. Expansion of the polyglutamine tract may lead to conformational changes to the 
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huntingtin protein that increase apoptotic properties of mHtt throughout the body (Sørensen, 
Fenger & Olsen, 1999). Further, the PI3K/AKT pathway, which Rhes directly activates and 
inactivates, is one of the most frequently targeted pathways for cancer treatment. AKT was 
originally discovered as an oncogene, and its significance in transformation and cancer was 
confirmed by studies showing that AKT is frequently amplified and overexpressed in human 
cancers (Cheng, Lindsley, Cheng, Yang & Nicosia, 2005).   
Given the ubiquitous expression of mHTT, select damage to organs with Rhes expression, the 
role of Rhes in proliferation and apoptosis, the role of mHtt in apoptosis, and increased toxicity 
of mHTT following SUMOylation, Rhes and mHtt specific toxicity may reflect an interaction of 
several processes which are normally protective, but destructive when combined. As mentioned 
previously, fragmentation of mHtt by Rhes increases toxicity compared to aggregation of mHtt 
(Subramaniam, Sixt, Barrow & Snyder, 2009). Additionally, co-expression of mHtt blocks Rhes 
induced autophagy (Mealer, Murray, Shahani, Subramaniam & Snyder, 2014), and Rhes induced 
autophagy is independent of mTOR. Rhes is down-regulated in HD, and because Rhes is crucial 
for so many cellular processes such as autophagy and cell survival, damage may occur as a result 
of decreased AKT/mTOR activation as well as inhibition of possible alternate compensatory 
processes (i.e. mTOR independent activation of autophagy by Rhes) due to its unique interaction 
with mHtt.  
1.4 3NP and Rhes 
Administration of 3NP, an irreversible inhibitor of the mitochondrial II complex, succinate 
dehydrogenase (SD), produces a selective striatal lesion similar to the selective striatal damage 
observed in HD. 3NP also produces a long-term potentiation (LTP) of glutamatergic NMDA-
16 
 
mediated synaptic excitation in MSNs (Calabresi et al., 2001). 3NP-LTP involves increased 
intracellular calcium and is critically dependent on endogenous dopamine acting via D2 
receptors, and negatively regulated by D1 receptors.  
In addition to altered DA and glutamatergic neurotransmission, many similarities exist between 
the 3NP model and HD. MSNs in HD patient brains show a significant decrease in SD activity, 
and as seen in several studies of neuroprotection in HD, 3NP appears to involve AKT signaling. 
Lithium reduced 3NP striatal neurodegeneration in rats by inhibiting activation of calpain (a 
calcium dependent protease involved in cell function), and reducing intracellular calcium levels 
(Crespo-Biel, Camins, Pallas, & Canudas, 2009). Calpain knockdown in a HD Drosophila model 
also protects against aggregation and toxicity of proteins in an autophagy dependent manner, as 
inhibition of calpain by calpastatin increases autophagosome levels and is also protective in a 
mouse model of HD (Menzies et al., 2014).  
Rhes involvement in both AKT and autophagy suggests that manipulation of Rhes expression 
should have a significant influence on 3NP toxicity; however, because Rhes is involved in 
activating and deactivating these processes, it is difficult to predict whether the influence would 
be protective or detrimental. A recent study found that Rhes deletion is neuroprotective in the 
3NP model (Mealer, Subramaniam & Snyder2013), indicating that down regulation of Rhes 
should also be protective.  
1.4.1 Protein Prenylation and Rhes 
Prenylation is a posttranslational process that occurs when hydrophobic molecules are added to a 
protein in order to aid in anchoring of the protein to its membrane. Protein prenylation occurs via 
the mevalonate synthetic pathway that ultimately affects the transfer of a functional farnesyl or 
 geranyl-geranyl molecule to a target protein
farnesyltransferase and geranylgeranyl transferase. Inhibition of these proc
anchoring of the target protein, and result in an inactive form of the protein
inhibition by drugs such as Simvastatin and Zoledronic Acid can disrupt this pathway (see Figure 
1.1).  
(Figure 1.1 : Overview of the mevalonate pathway.)
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Farnesylation of Rhes is required for it to become biologically active. An in vitro study of 
farnesyl deficiency cause by a mutated form of Rhes showed a significant reduction of Rhes 
binding to mHtt (Subramaniam, Sixt, Barrow & Snyder, 2009), however, replication of this 
finding in an animal model of HD has not yet been attempted.  
Additionally, this pathway involves cell signaling related to Rhes expression. Inhibition of the 
mevalonate pathway has been shown to modulate AKT (Kureishi et al., 2000; Larson-Casey, 
Murthy, Ryan, & Carter, 2014) and impair Insulin/IGF-1 signaling (Martı(nez-González, Viñals, 
Vidal, Llorente-Cortés & Badimon, 1997). Interestingly, the drug used in this study to inhibit 
farnesylation, Simvastatin, has been shown to both activate (Kureishi et al., 2000) and inhibit 
AKT (Kochuparambil, Al-Husein, Goc,  Soliman & Somanath, 2011); while glucose induced 
insulin secretion was shown to be inhibited by Simvastatin (Yada, Nakata, Shiraishi & Kakei, 
1999). The bisphosphonate Zoledronic Acid was also used in this study because it inhibits 
geranyl-geranylation. Further, Zoledronic Acid has been shown to inhibit AKT and reduce Bcl-2 
activity (Caraglia et al., 2007).  
1.5 Purpose and Hypothesis 
The purpose of this thesis was to further evaluate the influence of Rhes expression on the 
behavioral and neurodegenerative symptoms associated with HD. Using the 3NP model of HD, 
behavioral data were collected on animals treated with pharmacological inhibitors of farnsylation 
and geranyl-geranylation. 
Hypothesis:  3NP will induce motor and behavioral deficiencies that will be ameliorated by 
drugs that inhibit Rhes prenylation.   
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2. Method 
2.1 Animals 
Sixty male albino Hsd:ICR (CD-1)  mice were purchased from Harlan Laboratories 
(Indianapolis, IN). Mice weighed approximately 30 g on arrival, and were housed in groups of 
five. Temperature and humidity were under controlled conditions, and mice were kept on a 
normal 12:12 hour light:dark cycle (lights on 0700).   
Body weight was recorded during daily handling, and access to food and water was ad libitum. 
Animals were housed and handled in strict accordance with the regulations of the United States 
Public Health Service, and all conditions and procedures were approved by the University of 
New Orleans Institutional Animal Care and Use Committee.  
2.2 Drug Administration 
Drugs were dissolved daily prior to injections using sterile saline and administered in a volume 
of 10ml/kg. 3NP was dissolved to a concentration of 7.7mg/ml and neutralized to pH7.4 with 10 
Normal Sodium Hydroxide (Mealer et al., 2013) for a final concentration of 77mg/10 ml. While 
the concentration of 3NP remained the same throughout the experiment, the volume 
administered varied based on day of injection. Mice were injected once daily, starting at 50 
mg/kg with dosage increasing by 15% each day for a period of 7 days, and a cumulative dose of 
560 mg/kg at day 7.  
Simvastatin (40mg/kg) and Zoledronic Acid (1.0 mg/kg) or a combination of both drugs, were 
administered to animals along with 3NP for 7 days following random assignment to drug 
condition. Due to toxic effects of drug conditions involving 3NP+Saline, 3NP+Zoledronic Acid 
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and 3NP+Simvastatin+Zoledronic Acid, several animals did not survive to complete drug 
treatment, and no 3NP+Zoledronic Acid animals were behaviorally tested. Additional groups 
were added to the study in order to further study possible toxic effects of the drugs, and the dose 
of Zoledronic Acid was reduced to 0.5mg/kg and administered with either Simvastatin+3NP or 
Simvastatin+Saline (See Table 1.1).  Injections were ceased for the animals remaining in these 
groups prior to day 7, and behavior was recorded after 5 injections on day 6. 
Table 1.1: Drug Treatment Groups 
Squad Toxin Drug Tx Sample Size 
1 Sal Sal 12 
2 3NP Sal 12 
3 3NP Simvastatin 19 
4 3NP Zoledronate, 1 mg/kg 12 
5 3NP Simvastatin + Zoledronate, 1 mg/kg 12 
6 3NP Simvastatin + Zoledronate, .5 mg/kg 9 
7 Sal Simvastatin + Zoledronate, .5 mg/kg 6 
Total        82 
 
2.3 Behavioral Tests 
Twenty-four hours after the last drug injection all mice were tested using a battery of behavioral 
tests as described below. 
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Sucrose Preference Test 
 This test was used to examine HD-like symptoms such as anhedonia or lack of interest in 
seeking a reward (access to sucrose-adulterated drinking water). Mice have a bias for the sucrose 
solution, and a failure to consume the solution is considered to be indicative of anhedonia (Papp, 
Willner & Muscat, 1991). Mice were presented with two bottles with sipper tubes. One bottle 
contained water and the other contained a 30% sucrose solution. The bottles were weighed 
before the test, and placed in the cage with the mouse for one hour. After one hour, the bottles 
were weighed again, and a score was calculated by dividing the total amount of water intake by 
the total amount of water intake plus the total amount of sucrose intake and multiplied by 100:   
Index of Anhedonia % water preference  100   vol. water consumedvol. water  vol. sucrose consumed! 
Locomotor Behavior Test 
Mice were placed in the center of an elevated open field grid without any enclosure, and 
observed for 2 minutes. Number of squares crossed was recorded in order to capture any 
locomotor impairment. During this test, hypokinetic circling behavior was observed and 
recorded. These behaviors have previously been implicated in motor impairment and altered 
basal ganglia functioning (Miwa, Nishi, Fuwa & Mizuno, 1998; Löscher, 2010 Nambu et al., 
2011).  
Elevated Plus Maze 
 The elevated plus maze is used as a test of anxiety in mice (Pellow, Chopin, File & Briley, 
1985). The apparatus is a plus-shaped maze elevated 50 cm off the floor with two closed arms 
positioned across from each other, two open arms across from each other and a center area. The 
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four arms were made of strips of Plexiglas 10 cm wide and 50 cm long.  They were positioned on 
supports 50 cm above the floor of the testing room at 90o intervals and meet at a central square 
(10 cm2).  Two of the arms in 180o linear arrangement had walls 40 cm high that were 
interrupted at the central square. The two orthogonal arms contained no walls. The preference for 
being in closed arms over open arms is recorded to measure anxiety-like behavior. 
3. Results 
Data were screened for missing values and unequal sample sizes. Three cases were deleted from 
Saline+Saline Drug Group, and one case was deleted from the 3NP+Simvastatin Drug Group 
due to missing data. To create equal sample sizes from the remaining data, 6 cases were selected 
randomly from each group using SPSS case selection (N=30). 
Due to changes in study design, Number of Injections varied between groups, and was used as a 
covariate with Drug Group in all statistical analyses of behavior.  
 3.1 Sucrose Preference 
Homogeneity of regression showed that the interaction between Drug Group and Number of 
Injections was not significant (p=.915). Levene’s Test showed that homogeneity of variance 
could be assumed (p=.067). ANCOVA indicated that Number of Injections was not a significant 
covariate [F(1,24)=0.01, p=.915, eta2=.00], and indicated a strong significant relationship 
between Drug Group and Sucrose Preference Score [F(4,24)=3.93, p=.014, eta2=.40]. 
Group means from highest to lowest (see Figure 3.1a) were Saline+Saline (M=69.39), 
3NP+Simvastatin+Zoledronic Acid (M=54.04), Saline+Simvastatin+Zoledronic Acid 
(M=52.49), 3NP+Simvastatin(M=40.36) and 3NP+Saline (M=15.65). 3NP+Saline was 
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significantly different from Saline+Saline [t(10)=4.17, p=.002, 2-tailed]; 
3NP+Simvastatin+Zoledronic  Acid [t(10)=-4.97, p=.001, 2-tailed]; and 
Saline+Simvastatin+Zoledronic  Acid [t(10)=-3.29, p=.008, 2-tailed].  
 
(Figure 3.1a, Sucrose Preference-Results)  
3.2 Locomotor Behavior 
The variable Number of Squares crossed was positively skewed, and transformed via square root 
transformation.  Homogeneity of regression showed that the interaction between Drug Group and 
Number of Injections was not significant (p=.268), and Levene’s Test showed that homogeneity 
of variance could be assumed (p=.556). ANCOVA indicated that Number of Injections was not a 
significant covariate [F(1,24)=1.29, p=.268, eta2=.05], and indicated a strong significant 
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relationship between Drug Group and Number of Squares crossed [F(4,24)=4.06, p=.012, 
eta2=.40]. 
Group means from highest to lowest number of squares crossed were Saline+Saline (M=6.63), 
Saline+Simvastatin+Zoledronic Acid (M=4.59), 3NP+Simvastatin+Zoledronic Acid  (M=3.49), 
3NP+Simvastatin group (M=3.61), and 3NP+Saline group (M=2.70). Follow up comparisons 
showed that the Saline+Saline group was significantly different than the 3NP+Saline 
[t(10)=3.30, p=.008]; the 3NP+Simvastatin group [t(10)=2.64, p=.025]; the 
3NP+Simvastatin+Zoledronic  Acid group [t(10)=3.04, p=.013, 2-tailed]; and the 
Saline+Simvastatin+Zoledronic  Acid group [t(10)=2.44, p=.035, 2-tailed].  
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(Figure 3.2a, Locomotor Behavior-Results) 
3.3 Elevated Plus Maze 
Examination of homogeneity of regression showed that the interaction between Drug Group and 
Number of Injections was not significant (p=.240). Levene’s Test showed that homogeneity of 
variance could be assumed (p=.252). ANCOVA indicated that Number of Injections was not a 
significant covariate [F(1,24)=1.45, p=.240, eta2=.06], and indicated a strong significant 
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relationship between Drug Group and Number of Closed Arm Entries [F(4,24)=19.42, p=.000, 
eta2=.76]. 
The highest average number of closed arm entries from highest to lowest were Saline +Saline 
(M=10.83), Saline+Simvastatin+Zoledronic Acid (M=8.33), 3NP+Simvastatin+Zoledronic Acid 
(M=3.50), 3NP+Simvastatin group (M=2.33), and 3NP+Saline group (M=2.50). Follow up 
comparisons showed that the Saline+Saline group was significantly different from the 
3NP+Saline group [t(10)=5.22, p=.000];  3NP+Simvastatin group [t(10)=6.57, p=.000]; and the 
3NP+Simvastatin+Zoledronic  Acid group [t(10)=5.77, p=.000]. There was also a significant 
difference between the 3NP+Saline group and Saline+Simvastatin+Zoledronic Acid [t(10)=-
4.32, p=.002], and 3NP+Simvastatin and Saline+Simvastatin+Zoledronic Acid groups 
[t(10)=6.14, p=.000]. 
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(Figure 3.3a, Closed Arm Entries-Results) 
An additional ANCOVA was conducted using Closed Arm Entries as the independent variable, 
and the dichotomous variable Circling Behavior (0=no, 1=yes) observed during the locomotor 
test as a covariate with Drug Group. Examination of homogeneity of regression showed that the 
interaction between Drug Group and Circling Behavior was not significant (p=.240), and 
Levene’s Test showed that homogeneity of variance could be assumed (p=.157). ANCOVA 
indicated that Circling Behavior was a significant covariate [F(1,24)=10.68, p=.003, eta2=.31], 
and indicated a strong significant relationship between Drug Group and Closed Arm Entries 
when controlling for Circling Behavior [F(4,24)=17.37, p=.000, eta2=.74]. 
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4. Discussion 
These results suggest that prenylation inhibitors are not protective against 3NP induced 
behavioral changes in anxiety, as the significant differences between treatment groups appear to 
reflect motor impairment. Additionally, these treatments seem to exacerbate motor symptoms as 
reflected by the locomotor test and elevated plus maze. Surprisingly, the 
3NP+Simvastatin+Zoledronic Acid and 3NP+Simvastatin groups showed similar motor 
impairment, but sucrose preference results indicate that 3NP induced anhedonia was attenuated 
in the 3NP+Simvastatin+Zoledronic Acid group only. The combined motor impairment with 
attenuated anhedonia may indicate DA specific alterations in the 3NP+Simvastatin+Zoledronic 
Acid group as DA is believed to mediate sucrose preference (Towell, Muscat, & Willner, 1987) 
and may not represent deficits in non-dopaminergic neurotransmission.  
There may be several possible reasons for the detrimental effect of the drugs on motor behavior. 
First, as this was a simple behavioral study, we cannot be certain that the drugs acted to prevent 
the anchoring of Rhes without follow up studies examining striatal tissue. Second, even if the 
drugs were successful in preventing the anchoring of newly translated Rhes, there may still be an 
effect of previously anchored Rhes. Again, the only way to be certain of this would be a follow 
up study examining Rhes expression in brain tissue.  
Additionally, while the 3NP model replicates many features of HD, there are several studies that 
indicate a difference in cell survival processes. For instance, insulin and insulin growth factor 
signaling which are normally protective against HD damage are detrimental in the 3NP model. 
(Escartin, Boyer, Bemelmans, Hantraye & Brouillet, 2007). However, the authors reported no 
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change in COX activation following IGF-1 treatment. This is contradictory to another study 
showing an increase in COX following IGF-1, mediated protection of HD striatal cells (Ribeiro, 
Rosenstock, Oliveira, Oliveira, & Rego, 2014), suggesting that 3NP model cell survival 
mechanisms may be different than HD. 
A fourth possible explanation may be that decreasing Rhes expression is not protective in HD. 
Although these findings seem to contradict the protective effect of Rhes KO in a 3NP model 
(Meale, Subramaniam, & Snyder, 2013), they support other recent findings that suggest reduced 
Rhes expression actually enhances the HD phenotype (Lee, et al., 2014). Additionally, given the 
multiple roles for Rhes in AKT activation and cell function, it is likely that simply decreasing 
Rhes expression results in a deficit in cellular processing of both apoptosis and autophagy.  
The dual role of Rhes in AKT signaling may be explained by a recent finding in pancreatic 
cancer cells. Specifically, in pancreatic cancer cells, inhibition of either AKT or mTOR induces 
autophagy, but only inhibition of AKT leads to caspase-mediated apoptosis while inhibiting 
AKT in combination with inhibition of autophagy blocked cell death. These results suggest that 
AKT regulates both autophagy and apoptosis through different paths, and mTOR mediates 
autophagy but is not directly involved in cell death. Autophagy plays a role in cell survival by 
AKT, but only when mTOR independent pathways are simultaneously activated (Muilenburg, 
Parsons, Coates, Virudachalam & Bold, 2014), such as the mTOR independent functions of Rhes 
in autophagy and AKT activity (Mealer, Murray, Shahani, Subramaniam & Snyder, 2014).  
Due to the localization of Rhes and HD damage in both pancreatic and striatal cells these finding 
may explain some important contradictions as a result of the elusive functions of Rhes. Rhes 
activates and inhibits AKT, and was also recently found to activate autophagy independent of 
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mTOR. Therefore, Rhes may regulate signals that determine proliferation (i.e. AKT 
activation/phosphorylation), autophagy (i.e. AKT and mTOR), apoptosis (i.e. AKT 
deactivation/dephosphorylation) and/or autophagy with cell death. (i.e. mTOR independent 
activation). This contradictory process may explain the protective effect of combined Lithium 
and Rapamycin treatment for HD (Sarkar, Krishna, Imarisio, Saiki, O'Kane & Rubinsztein, 
2008). Additionally, the lithium treated phenotype of Rhes KO mice may also explain why the 
KO model was protective against 3NP while targeting Rhes expression is not. 
5. Conclusion 
Simply decreasing Rhes expression appears to be detrimental to behavioral outcomes in the 3NP 
model, and a follow up histological study is needed to be certain that the drugs used in this study 
prevented Rhes prenylation.  
Although Rhes is a crucial target for HD research, future studies may benefit from investigating 
striatal specific gene expression changes that may in turn influence Rhes function, and possibly 
explain the delayed onset of symptoms. For example, given the relationship between Rhes, 
growth factors, and AKT, age-related methylation of neurotrophic factors and their receptors 
may lead to altered cellular function.  
In particular, Glial derived neurotrophic factor (GDNF) may be a promising target. GDNF is 
mainly expressed in the striatum, and is crucial for striatal function and the survival of DA 
terminals where it is retrogradely transported from the striatum (Chermenina et al., 2006). 
Excitation of glutamate receptors mediates GDNF expression in the striatum (Ho, Gore, 
Weickert & Blum, 1995) and expression is altered following lithium treatment (Tunca et al., 
2014). Upregulation of GDNF has been shown to be protective in both a genetic and 3NP mouse 
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model of HD (Ebert, Barber, Heins & Svendsen, 2010; Lee et al., 2006), and exerts its protective 
effect via PIK3 (Anitha et al., 2006). Additionally, agonism of the GDNF receptor may enhance 
insulin releasing cells (Srinivasan, 2014), suggesting GDNF may be a promising target to include 
in future Rhes research. 
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